Pricing Log in Create free account
Saturday 17 October 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Abbott Laboratories (ABT) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Aug 20, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 3 added · 1 removed · 24 modified
P2I1A: no comparison — the Item was not found
8-K Jul 16, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 24, 2026 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
8-K Apr 10, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 16, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 23, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 9, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Feb 23, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Feb 20, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 1 added · 24 modified
1A: 3 added · 18 removed · 25 modified
7: 19 added · 19 removed · 59 modified
8-K Jan 22, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 12, 2025 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 5.04 Suspension of trading under employee benefit plans; 9.01 Financial statements and exhibits
8-K Nov 19, 2025 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 15, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.